SE9904652D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE9904652D0
SE9904652D0 SE9904652A SE9904652A SE9904652D0 SE 9904652 D0 SE9904652 D0 SE 9904652D0 SE 9904652 A SE9904652 A SE 9904652A SE 9904652 A SE9904652 A SE 9904652A SE 9904652 D0 SE9904652 D0 SE 9904652D0
Authority
SE
Sweden
Prior art keywords
novel compounds
medicaments
processes
preparation
general formula
Prior art date
Application number
SE9904652A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Baxter
Nicholas Kindon
Garry Pairaudeau
Bryan Roberts
Steve Thom
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9904652A priority Critical patent/SE9904652D0/xx
Publication of SE9904652D0 publication Critical patent/SE9904652D0/xx
Priority to AU22443/01A priority patent/AU775741B2/en
Priority to US10/149,760 priority patent/US6812226B2/en
Priority to BR0016396-1A priority patent/BR0016396A/pt
Priority to JP2001544703A priority patent/JP2003516978A/ja
Priority to CA002392894A priority patent/CA2392894A1/en
Priority to AT00986154T priority patent/ATE250590T1/de
Priority to CNB008189234A priority patent/CN1304382C/zh
Priority to KR1020027007697A priority patent/KR20020067554A/ko
Priority to PCT/SE2000/002504 priority patent/WO2001044213A1/en
Priority to DE60005560T priority patent/DE60005560T2/de
Priority to MXPA02005788A priority patent/MXPA02005788A/es
Priority to EP00986154A priority patent/EP1242396B1/en
Priority to IL15008500A priority patent/IL150085A0/xx
Priority to ZA200204429A priority patent/ZA200204429B/en
Priority to NO20022857A priority patent/NO323538B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9904652A 1999-12-17 1999-12-17 Novel Compounds SE9904652D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9904652A SE9904652D0 (sv) 1999-12-17 1999-12-17 Novel Compounds
IL15008500A IL150085A0 (en) 1999-12-17 2000-12-12 New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
AT00986154T ATE250590T1 (de) 1999-12-17 2000-12-12 Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
KR1020027007697A KR20020067554A (ko) 1999-12-17 2000-12-12 염증성 질환, 면역성 질환 또는 심혈관계 질환 치료용신규 ｐ2ｘ7 수용체 길항제
BR0016396-1A BR0016396A (pt) 1999-12-17 2000-12-12 Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
JP2001544703A JP2003516978A (ja) 1999-12-17 2000-12-12 炎症、免疫疾患または心血管疾患の治療に用いる新規なｐ２ｘ７受容体アンタゴニスト
CA002392894A CA2392894A1 (en) 1999-12-17 2000-12-12 New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
AU22443/01A AU775741B2 (en) 1999-12-17 2000-12-12 New P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
CNB008189234A CN1304382C (zh) 1999-12-17 2000-12-12 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
US10/149,760 US6812226B2 (en) 1999-12-17 2000-12-12 P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease
PCT/SE2000/002504 WO2001044213A1 (en) 1999-12-17 2000-12-12 New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
DE60005560T DE60005560T2 (de) 1999-12-17 2000-12-12 Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
MXPA02005788A MXPA02005788A (es) 1999-12-17 2000-12-12 Antagonistas del receptor p2x7 novedosos para uso en el tratamiento de enfermedades inflamatorias, inmunes o cardiovasculares.
EP00986154A EP1242396B1 (en) 1999-12-17 2000-12-12 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
ZA200204429A ZA200204429B (en) 1999-12-17 2002-06-03 New P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases.
NO20022857A NO323538B1 (no) 1999-12-17 2002-06-14 Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immun- eller kardiovaskulaere sykdommer, fremgangsmate for fremstilling derav, samt farmasoytiske blandinger som inneholder slike.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904652A SE9904652D0 (sv) 1999-12-17 1999-12-17 Novel Compounds

Publications (1)

Publication Number Publication Date
SE9904652D0 true SE9904652D0 (sv) 1999-12-17

Family

ID=20418188

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904652A SE9904652D0 (sv) 1999-12-17 1999-12-17 Novel Compounds

Country Status (16)

Country Link
US (1) US6812226B2 (xx)
EP (1) EP1242396B1 (xx)
JP (1) JP2003516978A (xx)
KR (1) KR20020067554A (xx)
CN (1) CN1304382C (xx)
AT (1) ATE250590T1 (xx)
AU (1) AU775741B2 (xx)
BR (1) BR0016396A (xx)
CA (1) CA2392894A1 (xx)
DE (1) DE60005560T2 (xx)
IL (1) IL150085A0 (xx)
MX (1) MXPA02005788A (xx)
NO (1) NO323538B1 (xx)
SE (1) SE9904652D0 (xx)
WO (1) WO2001044213A1 (xx)
ZA (1) ZA200204429B (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
MXPA03009602A (es) * 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
DK1975164T3 (da) 2001-04-18 2010-05-25 Euro Celtique Sa Octahydrobenzimidazolon-forbindelser som analgetika
PT1379246E (pt) * 2001-04-18 2009-01-14 Euro Celtique Sa Análogos de nociceptina
DE60229736D1 (de) 2001-04-18 2008-12-18 Euro Celtique Sa Spiroinden- und spiroindan-verbindungen
AU2002311833B2 (en) 2001-04-18 2005-04-28 Euro-Celtique S.A. Spiropyrazole compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
EP1474395B1 (en) * 2002-02-12 2007-10-17 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
DE602004007184T2 (de) 2003-04-17 2008-02-28 Affectis Pharmaceuticals Ag Mittel und Verfahren zur Diagnose und Behandlung affektiver Störungen
EP1626962B1 (en) * 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
ES2232292B1 (es) * 2003-07-30 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos.
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
US20080287467A1 (en) * 2004-05-06 2008-11-20 Gen Tamura Therapeutic Agent for Respiratory Diseases
MXPA06014022A (es) * 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP2269610A3 (en) * 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2006136791A1 (en) * 2005-06-21 2006-12-28 Astrazeneca Ab Polymorphisms and haplotypes in p2x7 gene and their use in determining susceptibility for atherosclerosis-mediated diseases
WO2007025366A1 (en) * 2005-08-29 2007-03-08 Irma Bernatchez-Lemaire Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
ES2601178T3 (es) * 2005-09-01 2017-02-14 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P3X2/3
WO2007025901A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CN101296907B (zh) * 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
AU2006296369B2 (en) * 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
ES2391107T3 (es) * 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
FR2892722B1 (fr) * 2005-11-02 2008-08-15 Clinigenetics Sa Composes de type methanone et leur utilisation dans des compositions pharmaceutiques notamment pour le traitement des maladies cardiovasculaires
US20070249666A1 (en) * 2006-03-31 2007-10-25 Bratcher Natalie A P2X7 Antagonists to Treat Affective Disorders
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2008060568A2 (en) * 2006-11-15 2008-05-22 Neurogen Corporation Amide-substituted aryl piperidines
EP2124562B1 (en) * 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
PE20091225A1 (es) * 2007-03-22 2009-09-16 Astrazeneca Ab Derivados de quinolina como antagonistas del receptor p2x7
US7932879B2 (en) * 2007-05-08 2011-04-26 Sony Ericsson Mobile Communications Ab Controlling electroluminescent panels in response to cumulative utilization
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
EP2942346B1 (en) * 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
EP2243772B1 (en) 2009-04-14 2012-01-18 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
CN102471284A (zh) * 2009-07-30 2012-05-23 弗·哈夫曼-拉罗切有限公司 作为p2x7调节剂的二氢嘧啶酮酰胺
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
WO2011072012A2 (en) 2009-12-08 2011-06-16 Vanderbilt University Improved methods and compositions for vein harvest and autografting
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
AU2011293612B2 (en) 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013012848A1 (en) * 2011-07-18 2013-01-24 Merck Patent Gmbh Benzamides
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
GB201508864D0 (en) * 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
CN109136361A (zh) * 2018-08-01 2019-01-04 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） P2x7受体在诊断和治疗类风湿关节炎方面的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
WO2001044213A1 (en) 2001-06-21
CN1304382C (zh) 2007-03-14
JP2003516978A (ja) 2003-05-20
NO323538B1 (no) 2007-06-04
DE60005560D1 (de) 2003-10-30
ATE250590T1 (de) 2003-10-15
US6812226B2 (en) 2004-11-02
AU775741B2 (en) 2004-08-12
KR20020067554A (ko) 2002-08-22
NO20022857L (no) 2002-08-01
US20030040513A1 (en) 2003-02-27
CA2392894A1 (en) 2001-06-21
EP1242396B1 (en) 2003-09-24
BR0016396A (pt) 2002-08-20
AU2244301A (en) 2001-06-25
EP1242396A1 (en) 2002-09-25
CN1434811A (zh) 2003-08-06
MXPA02005788A (es) 2002-09-18
ZA200204429B (en) 2003-09-03
DE60005560T2 (de) 2004-07-15
NO20022857D0 (no) 2002-06-14
IL150085A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
SE9904652D0 (sv) Novel Compounds
IS6658A (is) Ný efnasambönd
SE0104140D0 (sv) Novel Compounds
ATE433447T1 (de) Pyrimiidinverbindungen
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
SE0202133D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
SE9904738D0 (sv) Novel compounds
IS6520A (is) Ný efnasambönd
DE60214591D1 (en) Pyrazolpyrimidinfungizide
SE9901875D0 (sv) Novel compounds
DK1499590T3 (da) Piperidinderivater som kaliumkanalblokkere
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
SE0302139D0 (sv) Novel compounds
DE60112330D1 (en) Pyrazolopyridinderivate
TW200604197A (en) New compounds
SE0101038D0 (sv) Novel compounds
SE9902765D0 (sv) Novel compounds
SE0200919D0 (sv) Chemical compounds
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
SE0303280D0 (sv) Novel compounds
TR200401052T4 (tr) Yeni bileşikler
SE0302755D0 (sv) Novel compounds
SE9904128D0 (sv) Novel compounds